J. Gericke

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin

R. Hillenbrand, J. Ashton-Chess, M. Maurer, 2017, Theranostics.

Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study

Michael T. Beste, S. Kaiser, N. Hartmann, 2018, Allergy.

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.

Janko Brand, M. Maurer, M. Church, 2017, The Journal of allergy and clinical immunology.

Omalizumab may not inhibit mast cell and basophil activation in vitro

M. Maurer, M. Church, M. Metz, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.